Immuron Ltd.
(NASDAQ : IMRN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. 2.32%78.940.7%$1567.72m
JNJJohnson & Johnson 3.07%165.030.7%$1007.78m
PFEPfizer Inc. 1.74%42.040.9%$932.75m
ABBVAbbVie, Inc. 0.22%107.671.9%$683.45m
BMYBristol-Myers Squibb Co. 0.96%57.491.0%$657.66m
LLYEli Lilly & Co. 0.86%241.031.1%$614.58m
AZNAstraZeneca Plc 1.80%60.361.0%$372.91m
NVSNovartis AG 1.02%83.180.2%$176.13m
GSKGlaxoSmithKline Plc 1.61%39.270.2%$162.53m
RGENRepligen Corp. 1.99%269.026.8%$120.30m
NVONovo Nordisk A/S 1.47%104.950.1%$91.96m
VTRSViatris, Inc. 0.19%13.520.0%$90.77m
EDSAEdesa Biotech, Inc. 7.67%8.330.0%$76.27m
SNYSanofi 0.14%48.100.2%$62.97m
CRVSCorvus Pharmaceuticals, Inc. 3.68%4.790.7%$58.58m

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.